Recombinetics, a pioneer in gene editing solutions for human health and animal agriculture, announced Aug. 22 the completion of a $34 million Series A financing round.

“We’re pleased to announce the successful completion of our Series A Round,” Recombinetics president and chief executive officer Tammy Lee said. “This financing will allow us to accelerate commercialization of this transformative science to help find cures for human diseases, develop new regenerative medicine products and breed animals that are healthier and more productive.”

Company founder Dr. Scott Fahrenkrug added, “The success of this capital raise reflects confidence in the vision of Recombinetics’ founders and in the ability of the board of directors and management team to execute against that vision. The proceeds will accelerate the commercialization of genetic solutions for animal agriculture, swine pre-clinical research and so-called 'oinkubators' for producing therapeutic cells, tissues and organs.”

Proceeds will be used to accelerate new research and development by adding scientists and expertise focused on emerging science, including regenerative medicine; to continue to add to the company's robust intellectual property and patent portfolio; expand the laboratory, animal care and advanced reproductive facilities, and build out the business development, product marketing and management team to take advantage of licensing and co-development opportunities, Recombinetics said.

In conjunction with this financing, Recombinetics has converted or repaid all of its outstanding debt.

Founded in 2008, Recombinetics has a single gene-editing technology platform that supports three business lines: Acceligen (precision breeding to enhance health, well-being and productivity in food animals and aquaculture), Surrogen (gene-edited swine models of human diseases for biomedical research and pre-clinical trials by pharmaceutical and medical device companies) and Regenevida (development of human regenerative products, including cells, tissues and organ products in swine models for exotransplantation to humans).

Recombinetics has a global intellectual property portfolio, with 22 patents issued and more than 300 patent filings on gene editing methods, traits and novel reproduction methods in animals.